As for therapy, inhibiting AMPD3, could be beneficial to target before disease progression and can provide a greater efficacy than targeting the downstream effectors in ADPKD (please refer to Figure 3 for an overview of therapeutical targets). Here, AMPD3 is linked to autosomal dominant polycystic kidney disease.